Drug Profile
Iocanlidic acid I-123
Alternative Names: I-123 IPPALatest Information Update: 07 Jul 1999
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer King Pharmaceuticals Research and Development; Nonindustrial source
- Class Fatty acids; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery disease
Most Recent Events
- 07 Jul 1999 Discontinued-III for Coronary artery disease (diagnosis) in USA (unspecified route)
- 20 Feb 1997 Phase-III clinical trials for Coronary artery disease (diagnosis) in USA (unspecified route)